<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>GLP-1.app</title><link>https://glp-1.app/</link><description>GLP-1 research, explained.</description><language>en</language><item><title>What happens when you stop a GLP-1? What three trials found about weight regain</title><link>https://glp-1.app/stopping-glp-1-weight-regain/</link><guid>https://glp-1.app/stopping-glp-1-weight-regain/</guid><description>STEP 1, STEP 4 and SURMOUNT-4 followed people who stopped semaglutide or tirzepatide. Here is how much weight came back, how fast, and what it means.</description><category>Trial results</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>Semaglutide vs tirzepatide: which leads to more weight loss? What the head-to-head trial found</title><link>https://glp-1.app/semaglutide-vs-tirzepatide/</link><guid>https://glp-1.app/semaglutide-vs-tirzepatide/</guid><description>SURMOUNT-5 compared tirzepatide and semaglutide head to head for 72 weeks in 751 adults with obesity. The weight, waist and side-effect results, plus caveats.</description><category>Comparisons</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>How much protein do you need on a GLP-1? What the research says about protecting muscle</title><link>https://glp-1.app/protein-on-glp-1/</link><guid>https://glp-1.app/protein-on-glp-1/</guid><description>Part of the weight lost on semaglutide and tirzepatide is lean mass. Here is what the trials measured, what the 2025 nutrition advisory suggests for protein, and a quick calculator.</description><category>Nutrition</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>How much weight do people lose on oral semaglutide? What the OASIS trials found</title><link>https://glp-1.app/oral-semaglutide-weight-loss/</link><guid>https://glp-1.app/oral-semaglutide-weight-loss/</guid><description>OASIS 1 and OASIS 4 tested daily semaglutide pills for weight loss. Here is how much weight people lost, how it compares with the weekly shot, and side effects.</description><category>Trial results</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>How much weight do people lose on GLP-1 medication? What STEP 1 and SURMOUNT-1 found</title><link>https://glp-1.app/glp-1-weight-loss-results/</link><guid>https://glp-1.app/glp-1-weight-loss-results/</guid><description>The two landmark trials behind Wegovy and Zepbound, in plain English: average weight loss, how many people reached 10% or 20%, side effects and what the averages hide.</description><category>Trial results</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>How much weight do people with type 2 diabetes lose on a GLP-1? What STEP 2 and SURMOUNT-2 found</title><link>https://glp-1.app/glp-1-type-2-diabetes-weight-loss/</link><guid>https://glp-1.app/glp-1-type-2-diabetes-weight-loss/</guid><description>STEP 2 and SURMOUNT-2 tested semaglutide 2.4 mg and tirzepatide for weight loss in adults with type 2 diabetes. Here are the results and how they compare.</description><category>Trial results</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>Can tirzepatide help sleep apnea? What the SURMOUNT-OSA trials found</title><link>https://glp-1.app/glp-1-sleep-apnea/</link><guid>https://glp-1.app/glp-1-sleep-apnea/</guid><description>Two SURMOUNT-OSA trials tested tirzepatide in adults with obesity and moderate-to-severe sleep apnea. Here is what AHI means and how much it changed in a year.</description><category>Health conditions</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>How common is nausea on a GLP-1, and how long does it last? What the research says</title><link>https://glp-1.app/glp-1-side-effects-nausea/</link><guid>https://glp-1.app/glp-1-side-effects-nausea/</guid><description>Nausea, diarrhea, vomiting and constipation on semaglutide and tirzepatide: how often they happened in trials, when they peaked, and what helped.</description><category>Side effects</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>Does GLP-1 weight loss last? What two- and three-year trials found</title><link>https://glp-1.app/glp-1-long-term-results/</link><guid>https://glp-1.app/glp-1-long-term-results/</guid><description>STEP 5 followed semaglutide for two years and SURMOUNT-1 followed tirzepatide for three. Here is whether weight stayed off and what happened to diabetes risk.</description><category>Trial results</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>Does semaglutide help knee osteoarthritis pain? What the STEP 9 trial found</title><link>https://glp-1.app/glp-1-knee-osteoarthritis/</link><guid>https://glp-1.app/glp-1-knee-osteoarthritis/</guid><description>STEP 9 tested semaglutide in adults with obesity and painful knee osteoarthritis. Here is what happened to weight, pain and physical function over 68 weeks.</description><category>Health conditions</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>Does semaglutide lower the risk of heart attack and stroke? What the SELECT trial found</title><link>https://glp-1.app/glp-1-heart-select-trial/</link><guid>https://glp-1.app/glp-1-heart-select-trial/</guid><description>SELECT followed 17,604 adults with heart disease and overweight or obesity but no diabetes. What semaglutide 2.4 mg did to heart attacks, strokes and weight.</description><category>Health conditions</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>Does semaglutide or tirzepatide cause hair loss? What the research says</title><link>https://glp-1.app/glp-1-hair-loss/</link><guid>https://glp-1.app/glp-1-hair-loss/</guid><description>How often hair loss was reported in GLP-1 trials, why rapid weight loss is the leading explanation, and what is still unknown about the cause.</description><category>Side effects</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item><item><title>Can GLP-1 medicines help fatty liver disease (MASH)? What the trials found</title><link>https://glp-1.app/glp-1-fatty-liver/</link><guid>https://glp-1.app/glp-1-fatty-liver/</guid><description>Semaglutide&#x27;s phase 3 ESSENCE trial and tirzepatide&#x27;s phase 2 SYNERGY-NASH trial checked liver biopsies in people with MASH. Here is what changed, in plain words.</description><category>Health conditions</category><pubDate>Wed, 04 Nov 2026 00:00:00 +0000</pubDate></item></channel></rss>
